每周一次GLP-1受体激动剂度拉糖肽研发项目中胰腺安全性评估
汇总2/3期度拉糖肽试验共6005例2型糖尿病患者,比较度拉糖肽、安慰剂及活性对照药的急性胰腺炎风险。经裁定确认急性胰腺炎7例(度拉糖肽3例、安慰剂1例、西格列汀3例),暴露调整后度拉糖肽组发生率为0.85例/1000患者年,与安慰剂组3.52例/1000患者年相近。
要点
- 度拉糖肽组急性胰腺炎暴露调整发生率为0.85例/1000患者年,安慰剂组为3.52例/1000患者年。
- 西格列汀组急性胰腺炎发生率为4.71例/1000患者年,度拉糖肽组与之相近。
- 除甘精胰岛素外,所有治疗均观察到脂肪酶和胰淀粉酶中位数在正常范围内升高,未伴随不良事件。
核心结论
- 度拉糖肽治疗患者的急性胰腺炎暴露调整发生率与安慰剂相似,整个项目期间报告病例较少。
研究设计与样本
- 汇总2/3期度拉糖肽试验,共6005例2型糖尿病患者,度拉糖肽组4006例(剂量范围0.1-3.0 mg),活性对照组1541例(二甲双胍、西格列汀、每日两次艾塞那肽、甘精胰岛素),安慰剂组703例,其中245例安慰剂治疗患者后续接受度拉糖肽或西格列汀并纳入相应组,治疗长达104周。
主要发现
- 共151例患者的203起事件接受裁定(度拉糖肽组108起,包括安慰剂在内的对照组43起)。
- 经裁定确认急性胰腺炎7例:度拉糖肽组3例,安慰剂组1例,西格列汀组3例。
- 暴露调整发生率:度拉糖肽组0.85例/1000患者年,安慰剂组3.52例/1000患者年,西格列汀组4.71例/1000患者年。
- 每日两次艾塞那肽、二甲双胍或甘精胰岛素治疗患者中,经裁定未确认胰腺炎事件。
- 除甘精胰岛素外,所有治疗均观察到脂肪酶和胰淀粉酶中位数在正常范围内升高,这些变化未伴随不良事件。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the risk of acute pancreatitis during treatment with glucagon-like peptide 1 receptor agonist dulaglutide, placebo, and active comparators across phase 2/3 dulaglutide trials. RESEARCH DESIGN AND METHODS: A total of 6,005 patients with type 2 diabetes participated (dulaglutide group N = 4,006 [dose range 0.1-3.0 mg]; active comparator group [metformin, sitagliptin, exenatide twice daily, insulin glargine] N = 1,541; placebo group N = 703; 245 placebo-treated patients subsequently received dulaglutide or sitagliptin and were also included in these groups) for up to 104 weeks. The following events were adjudicated: investigator-reported pancreatitis, adverse events (AEs) of severe or serious abdominal pain of unknown etiology, and confirmed asymptomatic increases in pancreatic enzymes ≥3× the upper limit of normal range. RESULTS: Overall, 203 events from 151 patients underwent adjudication (dulaglutide group n = 108; comparator group including placebo n = 43). Acute pancreatitis was confirmed by adjudication in seven patients (dulaglutide n = 3, placebo n = 1, sitagliptin n = 3). Exposure-adjusted incidence rates were as follows: dulaglutide group 0.85 patients/1,000 patient-years, placebo group 3.52 patients/1,000 patient-years, sitagliptin group 4.71 patients/1,000 patient-years. No events of pancreatitis were confirmed by adjudication in patients treated with exenatide twice daily, metformin, or glargine. Increases in median values of lipase and pancreatic amylase within the normal range were observed with all treatments except glargine. These changes were not associated with AEs. CONCLUSIONS: The exposure-adjusted incidence rate of acute pancreatitis in dulaglutide-treated patients was similar to the rates with placebo, with few reported cases during the entire program.
引用
- Nauck MA, Frossard JL, Barkin JS, et al. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. Diabetes Care. 2017. PMID: 28283565. doi:10.2337/dc16-0984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。